Physician profile
Kent Posey
NPI 1689802258
$22,148.89
in general payments reported to CMS, 2019-2025
52 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $5,718 · 2021: $6,223 · 2022: $6,353 · 2023: $1,507 · 2024: $68.16 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715 · Education: $191 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.22 |
| Education | $190.95 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,961.54 | 2019-2021 | |
| Abbvie INC. | $5,345.08 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,329.47 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $1,581.70 | 2021 | |
| Medtronic Vascular, INC. | $1,109.03 | 2019 | |
| Biogen, INC. | $711.29 | 2019-2025 | Tysabri, Vumerity, Plegridy |
| Novartis Pharmaceuticals Corporation | $526.32 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $360.71 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Emd Serono, INC. | $336.40 | 2019-2023 | Mavenclad |
| Ucb, INC. | $326.84 | 2019-2025 | Briviact, Rystiggo |
| Supernus Pharmaceuticals, INC. | $191.48 | 2019-2022 | |
| Pfizer INC. | $172.47 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $147.57 | 2020-2023 | Ultomiris |
| Eisai INC. | $141.31 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $126.38 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Posey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.